Source: Pharmacy Times articles
Vepdegestrant was the first PROTAC to be evaluated in a phase 3 clinical trial.
Read More
Recent Content
- Policy Shifts Ahead: Expert Reviews Key Legislative Trends Reshaping Health-System Pharmacy
- A systematic review of direct oral anticoagulants for thromboprophylaxis in multiple myeloma
- Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC
- You Are Not Alone While Building a Support Team During Cancer Care
- Community Pharmacist Collaboration Expands Access to Long-Acting Injectable Antipsychotics
- Single Infusion of Cilta-Cel Yields 5-Year Progression-Free Survival in Multiple Myeloma
- ASCO 2025: Promising Safety and Efficacy of Encorafenib and Binimetinib in Resected Stage II Melanoma
- When Treatment Ends, Support Shouldn’t Stop in Cancer Care
- New Online Competency Modules Standardize CPA Pharmacist Training at Academic Medical Center
- Study Reveals Gaps in GINA Guideline Adherence for Asthma Treatment